Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns
Authors
Keywords
-
Journal
OncoImmunology
Volume 6, Issue 8, Pages e1338997
Publisher
Informa UK Limited
Online
2017-06-28
DOI
10.1080/2162402x.2017.1338997
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
- (2017) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Dosing Three‐Drug Combinations That Include Targeted Anti‐Cancer Agents: Analysis of 37,763 Patients
- (2017) Mina Nikanjam et al. ONCOLOGIST
- Next generation predictive biomarkers for immune checkpoint inhibition
- (2016) Yulian Khagi et al. CANCER AND METASTASIS REVIEWS
- Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
- (2016) Mina Nikanjam et al. INTERNATIONAL JOURNAL OF CANCER
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer
- (2016) Benjamin Herzberg et al. ONCOLOGIST
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
- (2016) Sariah Liu et al. Oncotarget
- Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
- (2016) Sadakatsu Ikeda et al. npj Genomic Medicine
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
- (2013) Yuting Ma et al. IMMUNITY
- Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials
- (2012) S. Gupta et al. JNCI-Journal of the National Cancer Institute
- CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma
- (2012) L. Wu et al. MOLECULAR CANCER THERAPEUTICS
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials
- (2012) Mitesh J. Borad et al. Journal of Cancer
- CD4+Foxp3+ Regulatory T-cell Impairment by Paclitaxel is Independent of Toll-like Receptor 4
- (2011) Y. Zhu et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
- (2010) R. K. Jain et al. CLINICAL CANCER RESEARCH
- Dose-escalation models for combination phase I trials in oncology
- (2010) Paul Hamberg et al. EUROPEAN JOURNAL OF CANCER
- Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials
- (2010) Christophe Le Tourneau et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Drug Combination Trial Design: Walking the Tightrope
- (2009) Paul Hamberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell-Mediated Antitumor Immunity Induced by DNA Vaccination
- (2008) C.-W. Tseng et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started